Abbott Park, Illinois – December 23, 2024 – Abbott has announced a significant milestone by reaching a settlement with DexCom, Inc. regarding ongoing patent disputes related to continuous glucose monitoring (CGM) products. This agreement marks the end of all pending legal cases across courts and patent offices globally.
Under the terms of the settlement, both companies have agreed to a mutual non-litigation clause concerning patent, trade dress, and design rights for the next decade. Notably, there are no financial exchanges involved in this agreement between Abbott and DexCom.
Abbott views this resolution as a positive step forward, enabling the company to dedicate its resources and efforts more completely toward aiding individuals with diabetes through its innovative technologies and services.
While the specific details of the settlement remain confidential, the agreement is poised to foster a collaborative environment in the diabetes care sector.
About Abbott:
Abbott is a leading name in healthcare dedicated to enhancing lives at every stage. Its diverse product portfolio includes advanced diagnostics, medical devices, nutritional products, and branded generics, serving individuals in more than 160 countries with a workforce of 114,000 professionals.
This settlement is a hopeful turn of events, paving the way for Abbott to continue its critical work in diabetes management without the distraction of legal disputes. Such agreements can ultimately lead to more innovation and improved patient care in the healthcare industry.